How the FDA Stifles New Cures, Part I: The Rising Cost of Clinical Trials

Published: Apr 25, 2012

Today, the Manhattan Institute released a study I authored, entitled “Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials.” (You can read the full report here.) The paper discusses how outdated FDA policies are making drug development too expensive and too risky. In this excerpt, I describe the factors that are driving up the cost of clinical trials.

Back to news